Author: Editor

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based on the entire concept…

iFrame is not supported! Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based…

Intra-arterial Versus Intravenous Gemcitabine Administration: PK Substudy within the Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer By Paula Novelli, MD At this year’s ASCO GI Symposium (in January 2023), our team presented intra-arterial gemcitabine versus intravenous gemcitabine PK substudy data within the RenovoRx TIGeR-PaC Phase III clinical trial. In a cohort of 13 patients, 7 patients were in the intra-arterial arm and 6 patients, the intravenous arm. Despite a 30% increased concentration in infusion in the intra-arterial arm, there was an average of 50% reduction in systemic drug exposure which is significant based on the entire concept…

Myelodysplastic Syndromes Treatment Update for 2023 ASH AML Inotuzumab Update [Slides] – Kiran Naqvi, MD MOASC By Kiran Naqvi, MD So today my talk was mainly highlighting the ASH abstracts or ash highlights of 2022. And I had the pleasure of presenting several abstracts, actually all of them, which I felt were really important. But some of the few that I wanted to mention that I think are important now is that we have really good experience with chemotherapy in our younger patients. And with the combination of Cytarabine, with Idarubicin or Anthracycline. But now we need to talk more…

MRD: Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia/Immunotherapy By Van Huynh, MD Today I spoke at MOASC (Medical Oncology Association of Southern California), and the focus was on acute lymphoblastic leukemia, or ALL, along with any new updates on immunotherapy in this population. Did anything stand out to you about these clinical trials? So I presented on three separate studies, and I think the general theme was that it acknowledged that the overall survival rate for adults with ALL (acute lymphoblastic leukemia) has historically been poor. But there have been many. There have been…

Myelodysplastic Syndromes Treatment Update for 2023 So briefly with regard to myelodysplastic syndromes MDS, I just wanted to discuss some of the proposed changes to classification, as well as some of the changes and updates and low-risk myelodysplastic syndromes, as well as high-risk myelodysplastic syndromes. So in June of 2022, the molecular international prognostic score was proposed. This has been long awaited based. Previously, we were using the I P S R. The problem with that system is that it didn’t include some of the important molecular findings that re leukemia were affecting outcome. So the purpose of the update…

Inotuzumab, GMALL, Ponatinib & Blinatumomab ASH Updates in Acute Lymphoblastic Leukemia By Van Huynh, MD Updates in acute lymphoblastic leukemia that was presented at ASH in New Orleans. So I think there were so many great talks. There were so many great talks and I decided I would focus on just three and really go into the details of each of those talks. I think there’s a theme there. So the first will be The trial by the gm, o l, which is the outcome of patients with newly diagnosed pH negative ALL treated according to a pediatric based regimen.…

Zanubrutinib compared to ibrutinib in chronic lymphocytic leukemia So I’m gonna start with chronic lymphocytic leukemia. And as part of late-breaking abstracts, we got this study which was zanubrutinib compared to ibrutinib before chronic lymphocytic leukemia.Relatively straightforward study design. These were previously treated patients, so one prior systemic therapy, measurable disease, no prior BTK inhibitors, and they were randomized one to one to zanubrutinib or ibrutinib. The primary endpoint was progression-free survival and treatment continued until progression or toxicity.And this was obviously a randomized study, so it was relatively balanced. The median age was about right for chronic lymphocytic leukemia…

2023 ASH Pregnancy Update Slides Etavopivat treatment Low molecular weight heparin versus a standard pregnancy care for women with recurrent miscarriage Okay, so this first abstract let’s talk about low molecular weight heparin versus a standard pregnancy care for women with recurrent miscarriage age and inherited thrombophilia. ALIFE2, which was an open-label phase three randomized control trial. As studies have shown an association between re. Carriages and inherited thrombophilia. And usually we just put the patient on ox if they have miscarriages, plus the proven thrombophilia. And then we go until the end of the pregnancy with ox. And…

2023 ASH AML Updates [Slides] – Kiran Naqvi MD – MOASC Acute myeloid leukemia updates from our recent ASH from 2022 By Kiran Naqvi, MD Acute myeloid leukemia. These are the updates from our recent ASH from 2022 Acute myeloid leukemia. These are the updates from our recent ASH from 2022. So moving on. The first abstract that I wanted to talk about was an acute promyelocytic leukemia standard risk not high risk where patient, this is a Chinese study, sorry. And. What they did was they compared ECTRA in combination with an oral formation of arsenic known as RGA Indigo.…

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients with primary refractory disease…

iFrame is not supported! Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients…

Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the phase 3 Transform study show in patients with relapsed or refractory large B-cell lymphoma (LBCL)? So with this ASH (American Society of Hematology) meeting, I was honored to present the primary analysis of the Transform trial, which is a randomized phase 3 trial comparing Lisocabtagene Maraleucel (liso-cel), an anti CD19 CAR T-cell product, with the standard of care as second line therapy in patients with relapsed or refractory large B-cell lymphomas. We specifically looked at patients with primary refractory disease…

MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD (minimal residual disease) technology.…

iFrame is not supported! MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD…

MRD: ASH 2022 Ben Derman the MRD2STOP Guide By Ben Derman, MD How can the MRD2STOP guide help patients with MRD? So the study that we have conducted or we’re currently conducting is really a prospective trial. And what we’re trying to do is take patients who have shown to have a durable, deep response to treatment for their myeloma and who are on maintenance therapy and see if they are able to stop their treatment, and then what happens after that happens. And so we’re really relying on MRD (minimal residual disease) testing or MRD (minimal residual disease) technology.…

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated for the disease and…

iFrame is not supported! Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated…

Isatuximab: ASH 2022 Irene Ghobrial Phase 3 Ithaca Study By Irene Ghobrial, MD What does the Ithaca clinical trials updated safety run-in results show for patients with High-Risk Smoldering Multiple Myeloma? We presented in the American Society of Hematology (ASH). Several abstracts related to MGUS and smoldering multiple myeloma. Some of them about risk stratification, who should be treated for smoldering myeloma because we know that many people are diagnosed with MGUS and smoldering myeloma, but not everyone will to active disease. So we need to be very selective in understanding better who should be treated for the disease and…

Emerging BTK inhibitors are positioned to change the landscape and impact your chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) treatment plans. Are you ready to incorporate these emerging therapies into your treatment plans? Dr. Sameer Parikh discusses these emerging BTK inhibitors for CLL / SLL, how they differ from current approaches, and future opportunities to introduce these therapies into your clinical decisions. Hear a patient case and the question and answer portion from this visiting lecture series. This activity also includes downloadable slides from the series to improve care for your patients with CLL/SLL. To claim credit: https://www.achlcme.org/btk-inhibitors-cll-sll-onctube

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize that they’re gonna be…

iFrame is not supported! Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize…

Anti-CD38: ASH 2022 Joshua Richter Treatment Patterns and Pt Outcomes By Joshua Richter, MD What is a Anti-CD38? And How can Anti-CD38 help patients with Relapsed/Refractory Multiple Myeloma (RRMM)? This study that we presented at this year’s ASH (American Society of Hematology) meeting was entitled, Enduring Responses After One Year Fixed Duration Cevostamab Therapy in Patients With Relapsed And Refractory Of Multiple Myeloma Early Experience From A Phase 1 study. Now, the bispecific antibodies are an exciting new field in myeloma, with the recent approval of Teclistamab and the recent filing of Talquetamab we recognize that they’re gonna be…

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas. So this was a…

iFrame is not supported! Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas.…

Pembro: ASH 2022 Craig Sauter After auto-SCT in T-Cell NHL By Craig Sauter, MD How does Pembrolizumab (MK-3475), also known as Pembro, after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma help? So this was a multi-side phase 2 single armed study. Originally designed with multiple cohorts looking at the role of Pembrolizumab (Pembro) maintenance, following high dose chemotherapy and autologous stem cell transplant in consolidation for various lymphomas. The abstract presented at ASH was cohort C, which is looking specifically at the patient’s proceeding to consolidative autonomous transplant for peripheral T-cell lymphomas. So this was a…

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some patients manifest a suboptimal…

iFrame is not supported! MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some…

MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative neoplasm) Study of the add-on of Parsaclisib to Ruxolitinib therapy? At the American Society of Hematology (ASH) 2022 in New Orleans, I had the opportunity to present the final safety and efficacy results of the add-on Parsaclisib study in patients with myelofibrosis and suboptimal response. This is the final results of a phase 2 study. Ruxolitinib has been approved for myelofibrosis, for clinical benefits. That includes splenic reduction, symptom improvement, and survival advantage. However, some patients manifest a suboptimal…

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical TrialBy Srdan Verstovsek, MD, PhDWhat were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal….JTA pathway, and this is because of our CE mutations in about 30% of the ET patients and 30%…

iFrame is not supported! PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. JTA pathway, and this is because of our CE mutations in…

PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of the PTG-300 Verify phase 3 clinical trial in polycythemia vera patients? The study (design) of interest is the primary session report of the development of new antibody, and that antibody is against a mutated calreticulin. Now, what is the mutated calreticulin? In all the patients with myeloproliferative, neoplasms being ET or PV (diagnosis polycythemia vera) or myelofibrosis, there is a hyperactivity of intercellular signal. JTA pathway, and this is because of our CE mutations in about 30% of the…

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses possible side effects from ROS1-TKIs, including dysgeusia, and neurologic events. We thank our sponsors for this year’s support! #novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim analyzes possible side effects of ALK-TKIs, including hypercholesterolemia, pulmonary events, and cognitive effects. We thank our sponsors for this year’s support! #novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim examines two rare side effects of EGFR-TKIs: pneumonitis and cardiotoxicity We thank our sponsors for this year’s support! #hormonetherapy #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses management of two possible side effects of EGFR-TKIs: stomatitis and diarrhea. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Chul Kim, Assistant Professor, Georgetown University; Hematology/ Medical Oncology; Attending Physician at MedStar Georgetown University Hospital, talks about Managing Treatment Toxicities: A Practical Approach. In this video, Dr. Chul Kim discusses dermatologic side effects of EGFR TKIs, including pruritis, xerosis, paronychia, and acneiform rash. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez examines oligoprogression specifically in EGFR Mutant NSCLC. We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez discusses how oligoprogression is treated, focusing on local therapies. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC.In this video, Dr. Narjust Florez discusses how to identify oligoprogression of disease.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Narjust Florez, Associate Director, Cancer Care Equity Program, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School; Thoracic Oncologist, Lowe Center for Thoracic Oncology, Dana Farber Cancer Insititute, discusses the Management of Oligoprogression in Mutated Advanced NSCLC. In this video, Dr. Narjust Florez explains what defines oligoprogression of disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not have any options for…

iFrame is not supported! Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not…

Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients with with -cell non-hodgkin lymphoma? I’m excited about this phase 2 Pembro (MK-3475) study, Pembrolizumab after autologous stem cell transplant in patients with T-cell lymphoma. As most rare for T-cell lymphomas have a poor prognosis and it’s really hard for developing new therapies given the heterogeneous nature of this disease and currently high dose chemotherapy and consolidation with an autologous stem-cell transplant is recommended in first remission. And however, at the moment we also do not have any options for…

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we have an established communication…

iFrame is not supported! MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we…

MRD: ASH 2022 Gayathri Ravi Induction Quadruplet Therapy in NDMM By Gayathri Ravi, MD What can induction quadruplet therapy do for patients with Newly Diagnosed Multiple Myeloma (NDMM) and does that include next-generation sequencing? So we adopted a institutional strategy to start do quadruplet induction therapy with a 4 drug-based induction for multiple myeloma from the March of 2020. And since UAB is the only transplant center in the state of Alabama, we have entire state of population who are transplant eligible and are nearly diagnosed with multiple myeloma referred to UAB for transplant. So we have an established communication…

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against specific (oncogenic) mutations…

iFrame is not supported! PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against…

PI3Kα: SABCS 2022 Axel Hoos STX-478 Xenograft Models Breast Cancer How can a PI3Kα inhibitor help patients suffering with breast cancer? The company that I represent is Scorpion Therapeutics, our focus is on elevating the entire game for precision oncology, so using targeted molecules that go after mutations and cancer and optimize outcomes for patients. So we call that Precision Oncology 2.0, now what we’re presenting here at SABCS is basically data on our lead compound, a PI3Kα inhibitor that is mutation selective. We call it STX-478, that has shown very high level, a selectivity against specific (oncogenic) mutations…

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an initial phase one Umbrella…

iFrame is not supported! Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an…

Sacituzumab Govitecan: SABCS 2022 Hope Rugo EAIRs of AEs TROPiCS-02 What does Sacituzumab Govitecan trial results show for patients with HR+/HER2- metastatic breast cancer (MBC)? Sacituzumab Govitecan is a first in class Trop-2-directed antibody-drug conjugates linked to a Topoisomerase 1 inhibitor. The active metabolite of Irinotecan SN-38 Sacituzumab is already FDA approved for the treatment of metastatic Triple-negative breast cancer (TNBC) in patients who’ve received at least one line of prior chemotherapy based on data from the ASCENT trial. Where it showed improvement in progression-free and overall survival compared to chemotherapy of physician choice. In an initial phase one Umbrella…

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based on our phase one.…

iFrame is not supported! ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based…

ARV-471: SABCS 2022 Ron Peck Phase 2 Expansion VERITAC Trial What can this PROTAC estrogen receptor degrader do for patients with metastatic breast cancer? ARV-471 is a PROTAC targeted protein degrader, so unlike surges, what it does is it tar targets the estrogen receptor and it hijacks. The cell zone machinery for degrading proteins the ubiquitous proteasome system. So this is a very potent ER degrader and the trial that was presented this morning was the VERITAC phase 2 study. And this is a study that was evaluating 2 different doses that were determined based on our phase one.…

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis in Cancer. In this video, Dr. Medhavi Gupta reiterates the importance of breast cancer screening in detection and treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta examines how treatment can look for patients diagnosed with breast cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta discusses symptoms that may be seen in patients with breast cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis. In this video, Dr. Medhavi Gupta examines the steps a patient could go through after an abnormality is found on a breast cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta discusses mammograms, ultrasounds, and MRIs for breast cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Medhavi Gupta discusses how common breast cancer is, and why it is crucial to get screened. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis. In this video, Dr. Rana McKay discusses why it’s crucial to get a prostate cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das examines the importance of patient centered care, including safety throughout the process, and equitable care for all. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses the importance of staging of cancer, and of testing for mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses the importance of staging of cancer, and of testing for mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das examines the first domain of quality cancer care: finding the cancer early. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das talks about goals for lung cancer advocacy, including broader testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses comprehensive care in lung cancer, and who is involved from screening to treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das explains the process of getting a lung cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das discusses which patients should receive lung cancer screening. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this 2022 Program: Testing and Early Diagnosis, Drs. Devika Das, Medical Oncologist, Hematologist, UAB Medicine, Clinical Assistant Professor, University of Alabama Birmingham; Dr. Rana McKay, Medical Oncologist, Associate Professor of Medicine, UC San Diego; and Dr. Medhavi Gupta, Hematologist-Oncologist, Roswell Park Comprehensive Cancer Center, Assistant Professor of Medicine, Brown University, present the importance about Testing and Early Diagnosis for Lung Cancer. In this video, Dr. Devika Das gives a brief overview of the importance of lung cancer screening during a pandemic. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the importance of biomarker testing, as well as disparities that exist in the field. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch examines liquid biopsies and their current and future role in diagnosis. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the ALK, RET, and MET mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss resources for patients with cancer. For a full list of resources, please visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program, or see these links, below: Making Cancer Decisions – https://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment UCSF’s Advanced Prostate Cancer Patient Guide – https://urology.ucsf.edu/sites/urology.ucsf.edu/files/uploaded-files/attachments/sduro0215_advanced_prostate_cancer_and_its_treatment-a_patient_guide.pdf Non-profit organizations – Prostate Cancer Foundation – https://www.pcf.org/ – American Society of Clinical Oncology – https://www.cancer.net/…

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss personal preferences in the decision-making process. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program For more, please visit https://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #prostatecancer #cancer #cancerresources #exelixis #lilly #genentech #hormonetherapy

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss the option of waiting to start hormone treatment. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program For more, please visit https://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #prostatecancer #cancer #cancerresources #exelixis #lilly #genentech #hormonetherapy

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch looks at KRAS mutations in advanced disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch talks briefly about Exon 20, and the importance of the Destiny Trial for patients with HER2. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the ADAURA Trial, which tested Osimertinib for early stage EGFR+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch looks at the drug combination of Amivantamab and Lazertinib in EGFR MET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses options when a patient with EGFR+ NSCLC develops acquired resistance to Osimertinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss his first option: starting hormone treatment immediately and its risks/benefits. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program For more, please visit https://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. #prostatecancer #cancer #cancerresources #exelixis #lilly…

For this series, Dr. Kwon discusses the decision-making process with Fred, who has recurrent prostate cancer and is making an important decision about hormone therapy. Fred candidly discusses his decision-making process and what he has learned through his cancer journey. In this video, Dr. Kwon and Fred discuss his treatment options for prostate cancer: starting androgen deprivation therapy immediately versus later. For resources and tools, please see the links available in the description of the last video in this series, or visit the cancerGRACE site at https://cancergrace.org/video-collection/patient-education-ambassador-program #prostatecancer #cancer #cancerresources #exelixis #lilly #genentech #hormonetherapy For more, please visit https://cancerGRACE.org/. To…

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch examines treatment options for EGFR+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch discusses the advantages of Next Generation Sequencing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch examines the concept of targeted driver mutations in NSCLC treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer. In this video, Dr. Fred Hirsch talks about the changes in the first-line treatment of metastatic NSCLC over the past 2 decades. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold examine a drug that treats oral mucositis. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold look at the importance of CT and HPV DNA in treatment of head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold examine possible treatment combinations for head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold discuss how to treat patients with recurrent or metastatic head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold talk about the effectiveness of immunotherapy in head and neck cancer treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist, specialized in lung, head and neck, Professor, Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology, UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. In this video, Drs. Sheth and Gold examine the benefit of weekly cisplatin usage for patients with head and neck cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

In this video series Dr. Kathryn Gold, Medical Oncologist specializing in lung, head and neck cancers, Professor with the Department of Medicine, UC San Diego, and Dr. Siddharth Sheth, Medical oncologist, Assistant Professor of Medicine, Division of Medical Oncology at UNC Chapel Hill, discuss the newest updates in head and neck cancer, presented at ASCO 2022. Drs. Sheth and Gold discuss emerging information on deintensification for nasopharyngeal cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

El Dr. Eric Singh, uno de los participantes en el Programa de Embajadores de Educación para Pacientes GRACE del año pasado, produjo este excelente video para nuestra comunidad de habla hispana, sobre visitas de oncología médica. Este video proporciona una guía del paciente para la visita inicial de oncología médica. Para descargar las notas útiles del Dr. Singh, visite https://cancergrace.org/video-collection/patient-education-ambassador-program, https://cancergrace.org/sites/default/files/2022-08/GUIÏA%20DEL%20PACIENTE%20PARA%20LA%20VISITA%20INICIAL%20DE%20ONCOLOGIÏA%20MEÏDICA_Spanish.pdf Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.

Dr. Eric Singh, one of the participants in this past year’s GRACE Patient Education Ambassador Program, produced this great video for our English-speaking community, on medical oncology visits. This video provides a patient’s guide to the initial medical oncology visit. To download Dr. Singh’s helpful notes, please visit https://cancergrace.org/video-collection/patient-education-ambassador-program and https://cancergrace.org/sites/default/files/2022-08/Patient%20Guide%20to%20Initial%20Medical%20Oncology%20Visit_English.pdf. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes look at the Checkmate 816 study, which examined chemo combined with Opdivo in patients with 1B to 3A disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss the results of the Skyscraper Trial, which looked at small cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes examine the use of Patritumab Deruxtecan in patients without particular mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss the use of Durvalumab in patients with EGFRm+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss the use of Rybrevant/Lazertinib in patients with EGFRm+ acquired resistance. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes look at data that suggests patients with previously treated advanced NSCLC may respond to Keytruda combined with Anti-VEGF Treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes discuss a study showing positive results for Adagrasib in previously treated disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video Drs. West, Naidoo, and Lopes examine an FDA analysis that states patients with a KRAS Mutation should opt for chemo and immunotherapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video, Drs. West, Naidoo, and Lopes discuss if patients with high PD-L1 should have immunotherapy alone, or combine with chemotherapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s post-ASCO Lung Cancer roundtable review, Drs. H.Jack West, Oncologist with City of Hope Comprehensive Cancer Center and Founder and President of GRACE, Jarushka Naidoo, Medical Oncologist and Assistant Professor with Sidney Kimmel Cancer Center at Johns Hopkins, and Gilberto Lopes, Chief Medical Oncologist with Sylvester Comprehensive Cancer Center, discuss the newest updates in lung cancer, presented at ASCO 2022. In this video, Drs. West, Naidoo, and Lopes discuss a study that showed overall survival increased with thorough molecular testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Melina Marmarelis explains how mesothelioma is diagnosed and staged. Melina Marmarelis 博士解释了间皮瘤是如何诊断和分期的。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Melina Marmarelis discusses the ways mesothelioma may be treated in the future. Melina Marmarelis 博士讨论了未来治疗间皮瘤的方法。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr, Chul Kim discusses Amivantamab and Mobocertinib, and their role as treatments for EGFR Exon-20 Insertion Mutations Chul Kim 博士讨论了 Amivantamab 和 Mobocertinib，以及它们作为 EGFR 外显子 20 插入突变治疗的作用 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, GRACE is happy to offer updates to our Lung Cancer Video Library translated and voiced by Oliver Zheng. In this video translation, Dr. Ibiayi Dagogo-Jack explains the concept of “skipping” in Exon-14 NSCLC. Ibiayi Dagogo-Jack 博士解释了 Exon-14 非小细胞肺癌中”跳过”的概念。 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For our Mandarin-speaking community, Oliver Zheng offers translated updates to our Lung Cancer Video Library. In this video translation, Dr. Christina Baik looks toward the future of treatments for patients with EGFR Exon-20. Christina Baik 博士展望 EGFR Exon-20 患者治疗的未来 For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza las formas de reducir el riesgo de cáncer de cabeza y cuello, con énfasis en la vacuna contra el VPH. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza los beneficios de las pruebas regulares de detección de cáncer de cabeza y cuello. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck

El Dr. Jared Weiss se une a nosotros para analizar la importancia de las pruebas y el diagnóstico temprano en la atención del cáncer, con énfasis en los cánceres de cabeza y cuello. En este video, el Dr. Jared Weiss analiza los factores de riesgo de los cánceres de cabeza y cuello. Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. Gracias a nuestros patrocinadores. #Exelixis y #Merck

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses ways to lower your risk of head and neck cancer, with emphasis on the HPV Vaccine. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses the benefits of regular screening for head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck

Dr. Jared Weiss joins us to discuss the importance of testing and early diagnosis in cancer care, with a concentration in head and neck cancers. In this video, Dr. Jared Weiss discusses the risk factors for head and neck cancers. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. Thank you to our sponsors! #Exelixis and #Merck

July 30, 2022 – full ONDEMAND video For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School. In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez Mañana, Liu, and Gainor discuss the case…

For this year’s update to the Case-Based Panel Discussions program, we are pleased to work with Drs. Ana Velazquez Mañana, Medical Oncology Fellow, UCSF Helen Diller Family Comprehensive Cancer Center, Stephen Liu, Associate Professor of Medicine, Georgetown University, Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, and Justin Gainor, Director, Center for Thoracic Cancers, Director of Targeted Immunotherapy, Associate Professor of Medicine at Harvard Medical School.  In this series, the doctors discuss a variety of cases based on real-life scenarios. In this video Drs. Velazquez-Manana, Liu, and Gainor discuss a 66-year-old patient…

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…

We are excited to bring new and updated information to share through our Lung Cancer Video Library. For this video series, we are pleased to work with Dr. Christina Baik, Oncologist at Seattle Cancer Care Alliance, Associate Professor of Medicine at the University of Washington, and Associate Professor, Clinical Research Division of the Fred Hutchinson Cancer Care Research Center; Dr. Melina Marmarelis, Hematology and Oncology professional and Assistant Professor of Medicine at the Hospital of the University of Pennsylvania; Dr. Sandip Patel, Medical Oncologist and Associate Professor of Medicine at UC San Diego Health; Dr. Tejas Patil, Medical Oncologist and…

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about these patients age group are…

Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about these patients age group are…

iFrame is not supported! Sociodemographic: SABCS 2022 Megan Kruse Disparities in AYA Breast Cancer What does the sociodemographics present study of Adolescent and Young Adults (AYA) patients with invasive breast cancer tell us? This study was presented at the San Antonio Breast Cancer Symposium (SABCS) as a poster in 2022, and it’s a look at the effect of sociodemographic disparities on overall survival for adolescent and young adult patients with invasive breast cancer. So this is a unique population of patients within the breast cancer community. In the Adolescent and Young Adults (AYA) group, and we think about…

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of 0.28 in favor of T-DXd,…

iFrame is not supported! DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of…

DESTINY-Breast03: SABCS 2022 Sara Hurvitz Updated Survival Results What do the updated survival results deruxtecan versus trastuzumab emtansine reveal for this metastatic breast cancer clinical trial? The DESTINY-Breast03 clinical trial (Daiichi Sankyo and AstraZeneca’s Trastuzumab) was a phase 3 study comparing Trastuzumab Deruxtecan to Trastuzumab Emtansine in patients treated with HER2-positive metastatic breast cancer that had previously been treated with Trastuzumab and a taxane. The first analysis of the trial results were presented in September of 2021 at ESMO where a statistically significant improvement in progression-free survival was demonstrated with the hazard ratio of 0.28 in favor of T-DXd,…

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma patients is a 6…

iFrame is not supported! GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma…

GC012F: ASH 2022 Wendy Li First-Line Therapy Newly Diagnosed MM By Wendy Li, MD How can GC012F help patients with newly diagnosed multiple myeloma? This is a phase 1 open label single arm study of a BCMA/CD19 Dual-Targeting CAR T cells, FasTCAR-T therapy for first line therapy for transplant eligible high newly diagnosed multiple myeloma. What is the standard of care for patients with multiple myeloma? Yes, compare with the standard of the care. Yeah, I think the very important things to understand that’s a current standard of care. Yeah, for newly diagnosed multiple myeloma patients is a 6…

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC 0 from our collaboration…

iFrame is not supported! IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC…

IHC 0 HER2: SABCS 2022 Gerard Oakley Deep Learning-Based Assessment By Gerard Oakley, MD What is IHC 0 in HER2 breast cancer patients, and how can it help? So the current study is really an expansion on previous press releases that we’ve made about the development of an algorithm that we call HER2 complete which is designed to evaluate HER2-positive and negative breast cancer cases. And we’ve really aimed it for the IHC 0 category within HER2 testing. And so what we’ve done is we were able to access an additional 900 plus cases within IHC 0 from our collaboration…

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic leukemia) has shifted over…

iFrame is not supported! CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic…

CLL Treatments: ASH 2022 Brian Koffman Understanding Pts with CLL By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd How will understanding patients with chronic lymphocytic leukemia (CLL) help with their treatments? First, I want to say I’m very thankful to have the opportunity to present this study on behalf of my co-investigators. We presented this as a poster presentation at ASH 2022 in New Orleans. The title is “Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments.” In the way of background, I think all clinicians know how radically the treatment paradigm in CLL (chronic lymphocytic leukemia) has shifted over…

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has not yet received the…

iFrame is not supported! Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has…

Navitoclax: ASH 2022 Jalaja Potluri Disease Modification in Myelofibrosis By Jalaja Potluri, MD How can this study help modify myelofibrosis? Navitoclax is the investigational drug, which is not currently approved. It is being studied in a condition called Myelofibrosis. It’s a bone marrow disease where there’s changes in the blood counts and patients are symptomatic, with enlarged spleen. It is being studied in a phase 2 program, and the data that are being discussed are from this ongoing phase II study. It has multiple cohorts. The data that was just presented represents a population that has not yet received the…

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it has three domains that…

iFrame is not supported! TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it…

TriTAC: ASH 2022 Al-Ola Abdallah Updated Interim Results HBN217 By Al-Ola Abdallah, MD What are the updated interim results from the HPN217 (Tri-specific T Cell Activating Construct [TriTAC®]) clinical trials in TRiTAC targeting BCMA for RRMM Patients in therapeutic T-cells? Today we’re gonna talk a little bit about HBN217 (Tri-specific T Cell Activating Construct [TriTAC®]), which is a TriSpecific T-cell activating construct and relapse refractory myeloma. And this type of treatment is designed for a phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and activity of this treatment. The mechanical action of this drug, it has three domains that…

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get the inhibition of other…

iFrame is not supported! Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get…

Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML By Professor Timothy Hughes, MD, MBBS, FRACP, FRCPA How can Asciminib help patients with CML and were there any significant side effects? Asciminib is very much a new compound with a quite a unique mechanism of action, unlike all of the other Tyrosine kinase inhibitors (TKIs) which work by inhibiting BCR-ABL by competing with ATP, Asciminib actually binds to a distinct site in BCR-ABL, called the myristate site and switches off BCR-ABL activity by that mechanism. That provides a major advantage because you do not get the inhibition of other…

Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we can give CAR T-cell…

iFrame is not supported! Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we…

Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with RR large B-cell lymphoma? Today I’m going to be talking about the outreach study. So outreach study is the phase 2 prospective study evaluating the safety and efficacy of treatment with chimeric antigen receptor T-cell therapy Lisocabtagene Maraleucel (Liso-cel). Liso-cel (Liscobtagene Maraleucel) in patients with third line or later relapse or refractory large B-cell lymphoma across outpatient and inpatient setting at community or non university sites in the United States. So we know that we can give CAR T-cell…

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical outcomes by race, and…

iFrame is not supported! RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical…

RxPONDER: SABCS 2022 Yara Abdou Racial Disparities SWOG S1007 The focus was on patient-reported anxiety and fatigue in women, what were the findings? Our study was focused on determining whether there were racial or ethnic disparities in patient outcomes in the RxPONDER trial. As a reminder, the RxPONDER trial is what established the clinical utility of the 21-gene recurrence score in participants with hormone positive HER2 negative breast cancer and 1–3 positive lymph nodes. Our study objectives were to evaluate the entire cohort for clinical and pathologic characteristics by race, analyze the clinical outcomes by race, and…

Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36 months of adjuvant endocrine therapy.…

iFrame is not supported! Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36…

Endocrine Therapy: SABCS 2022 Halle Moore POSITIVE Trial Breast Cancer How does endocrine therapy (aromatase inhibitor) effect women with endocrine responsIVE breast cancer? The POSITIVE study which was presented at this year’s San Antonio Breast Cancer Symposium (SABCS) was a prospective clinical trial designed to evaluate the safety of and pregnancy outcomes with interrupting endocrine therapy for early stage hormone receptor positive breast cancer in order to attempt pregnancy. Young women with early stage hormone receptor positive breast cancer were eligible for the trial if they desired pregnancy and had completed 18 to 36 months of adjuvant endocrine therapy.…

iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that…

iFrame is not supported! IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that…

IPSS: ASH 2022 Roger Lyons Treatment Pattern and Overall Survival MDS By Roger M. Lyons, MD, FACP What is the IPSS and the IPSS-R scoring systems and how will this help patients with MDS? This is a study that took place over 10 years looking at the US Oncology iKnowMed medical record system to define the course of patients with a myelodysplasia. There were 1400 physicians involved in the trial. So it’s a huge database. Of course, this was not a prospective study, so some of the data is not absolutely in a form that can you be used…

Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is that compliment plays an…

iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is…

Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the diagnosis and treatment of pregnant women with a prior diagnosis of TMAs, or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy, specifically TTP and complement mediated HRES, are rare disease in these patients. Eventually, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for that? And the reality is that compliment plays an…

FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great treatment options, but many…

iFrame is not supported! FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great…

FGFR2: Breast Cancer Suneel Kamath SABCS 2022 ReFocus Trial How can FGFR2 inhibitors like RLY-4008 help with patients suffering with cholangiocarcinoma and what makes it a clinical significance? The ReFocus study is a trial, it’s a phase 1/2B study including all solid tumors, mainly focused on cholangiocarcinoma, and some other separate subsets including breast cancer, some of the GYN malignancies as well. Looking at a novel FGFR2 inhibitor RLY-4008. So there are several existing FGFR2 (tyrosine kinase) inhibitors in cholangiocarcinoma and bladder cancer. And all of them look to be quite effective and really great treatment options, but many…

Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk of breast cancer specific…

iFrame is not supported! Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk…

Bisphosphonates: Breast Cancer Julia Foldi SABCS 2022 Cohort Study How can BMAs (zoledronic acid) help oncology patients with early-stage breast cancer in the United States and not in other countries? I’m talking about our study looking at patterns of adjuvant bone modifying use in patients with early stage breast cancers. Bone modifying agents, particularly bisphosphonates, not only help preserve bone density (or bone material loss) in postmenopausal women receiving endocrine therapy for treatment of breast cancer, but we also know that they reduce the risk of breast cancer recurrence as well as reduce the risk of breast cancer specific…

Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of failure to front-line therapy,…

iFrame is not supported! Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of…

Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab either with our without Bendamustine show in this clinical trial? So our study is a retrospective study of patients treated with Polatuzumab Vedotin which is a CD79 antibody drug conjugate in combination with Rituximab plus the addition of Bendamustine in the patient population with relapsed refractory large b-cell lymphoma (RR DLBCL). Our aim was to analyze the institutional outcomes of patients treated with this regimen. And as well, we wanted to look at the pattern of failure to front-line therapy,…

Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality is that complement plays…

MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing) index with the low…

iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality…

Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs? I will be discussing the clinical diagnosis and treatment of pregnant women with a prior diagnosis of TMAs or thrombotic microangiopathy. This is very important because while thrombotic microangiopathy (TMA), specifically TTP and complement-mediated HRES are rare diseases, patients eventually may become, want to become pregnant, and there’s a number of uncertainties in this field. Should we monitor them? How do we monitor them? How frequently, what labs do we use for. And the reality is that complement plays…

iFrame is not supported! MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing)…

MammaPrint: Breast Cancer Dr. Nasrazadani SABCS 2022 70-gene 10 Year Follow Up What has this 10 year follow up on this clinical data shown in patients with early-stage breast cancer? So this is in a real world retrospective study utilizing the 70-gene MammaPrint assay in a cohort of patients at UPMC of patients that were diagnosed with early stage breast cancer between 2005 to 2008, specifically looking at the ability to prognosticate, with regard to distant metastasis free interval, in patients that have an either low risk or high risk MammaPrint (test or genetic testing) index with the low…

iFrame is not supported! Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers) genetics and inflammatory markers that predict chemotherapy-induced peripheral neuropathy? So the GENIE Study aims to develop biomarkers for peripheral neuropathy in patients treated with taxane chemotherapy for breast cancer patients. Peripheral neuropathy occurs in about 70% of patients with breast cancer. They’re treated with taxanes. Most of those patients will have relatively mild symptoms that resolve shortly after their infusion. But in a subset of patients, those symptoms can be pretty severe. And in some patients, that can also persist…

Biomarkers: Breast Cancer – Daniel Rotroff SABCS 2022 GENIE Trial What will help identify (biomarkers) genetics and inflammatory markers that predict chemotherapy-induced peripheral neuropathy? So the GENIE Study aims to develop biomarkers for peripheral neuropathy in patients treated with taxane chemotherapy for breast cancer patients. Peripheral neuropathy occurs in about 70% of patients with breast cancer. They’re treated with taxanes. Most of those patients will have relatively mild symptoms that resolve shortly after their infusion. But in a subset of patients, those symptoms can be pretty severe. And in some patients, that can also persist for months or even…

iFrame is not supported! Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib reveal in patients with relapsed refractory CLL and SLL? So we presented follow up from the phase 1/2 BELLWAVE-001 study of nemtabrutinib in patients with relapsed refractory CLL and SLL. So nemtabrutinib is a non-covalent BTK bruton tyrosine kinase inhibitors (BTKis). It was designed to be able to bind BTK outside of the C481 site, which is where the covalent BTK inhibitors bind. So the idea is that this will be an effective agent, even if…

Nemtabrutinib: Jennifer Woyach, MD ASH 2022 – BELLWAVE-001 Study By Jennifer Woyach, MD What did the BELLWAVE-01 study on Nemtabrutinib reveal in patients with relapsed refractory CLL and SLL? So we presented follow up from the phase 1/2 BELLWAVE-001 study of nemtabrutinib in patients with relapsed refractory CLL and SLL. So nemtabrutinib is a non-covalent BTK bruton tyrosine kinase inhibitors (BTKis). It was designed to be able to bind BTK outside of the C481 site, which is where the covalent BTK inhibitors bind. So the idea is that this will be an effective agent, even if patients develop resistance mutations…

iFrame is not supported! Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood cancer treatment for the patient population with AML? There is such a momentum of new data for acute myeloid leukemia (AML blood cancer) here at this congress, and compared with the early days of chronic myelogenous leukemia and multiple myeloma, where such great medical progress was made, within a few years, we (Notable Labs) had the opportunity to present data just here in New Orleans on juvenile myelomonocytic leukemia. It’s a very rare disease. It is…

Notable Labs: Thomas Bock ASH 2022 The Future of AML Treatment By Thomas Bock, MD, MBA Where is the blood cancer treatment for the patient population with AML? There is such a momentum of new data for acute myeloid leukemia (AML blood cancer) here at this congress, and compared with the early days of chronic myelogenous leukemia and multiple myeloma, where such great medical progress was made, within a few years, we (Notable Labs) had the opportunity to present data just here in New Orleans on juvenile myelomonocytic leukemia. It’s a very rare disease. It is for collaboration with UCSF’s…

iFrame is not supported! Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and how can it help patients with HR+ HER2-negative breast cancer? The SWOG S1207 was a trial in the adjuvant breast cancer setting for patients that have hormone receptor positive and HER two negative breast cancer that certain criteria for being at high risk (increased risk) for a distant recurrence. So all patients in this study got endocrine therapy, it could be endocrine therapy of choice, so ovarian function suppression, Tamoxifen, or an aromatase inhibitor and then they were randomized…

Everolimus: Julie Gralow SABCS 2022 SWOG S1207 in HER2- Breast Cancer What is Everolimus and how can it help patients with HR+ HER2-negative breast cancer? The SWOG S1207 was a trial in the adjuvant breast cancer setting for patients that have hormone receptor positive and HER two negative breast cancer that certain criteria for being at high risk (increased risk) for a distant recurrence. So all patients in this study got endocrine therapy, it could be endocrine therapy of choice, so ovarian function suppression, Tamoxifen, or an aromatase inhibitor and then they were randomized to either placebo or…

iFrame is not supported! VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the VERIFY clinical trial of PTG-300 help patients with polycythemia vera? I’m going to talk about this poster number 1709, which is a presentation of the VERIFY study, a phase 3 study of the Hepcidin Mimetic Rusfertide, also known as PTG-300. In patients with polycythemia vera, this is the study that is underway based on the outcome of the phase 2 open label study with this particular medication. Now, Rusfertide is hepcidin mimetic. What that means…

VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the VERIFY clinical trial of PTG-300 help patients with polycythemia vera? I’m going to talk about this poster number 1709, which is a presentation of the VERIFY study, a phase 3 study of the Hepcidin Mimetic Rusfertide, also known as PTG-300. In patients with polycythemia vera, this is the study that is underway based on the outcome of the phase 2 open label study with this particular medication. Now, Rusfertide is hepcidin mimetic. What that means is that it is…

RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU,

iFrame is not supported! SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn cells into antigen-presenting cells? Now our next presentation was looking at our pipeline development, capitalizing on the observations we’ve. With the Bria-IMT therapy we’ve decided to take our cell line and some other cancer cell lines and to modify them so that they express different HLA types. I mentioned in our monotherapy and in our combination therapy experience with Bria-IMT, that there appears to be a clinical benefit associated with having an HLA match. With the Bria-IMT cell line.…

SV-BR-1-GM: Turning Cells into Antigen-presenting Cells Dr. Williams SABCS 2022 How does SV-BR-1-GM help turn cells into antigen-presenting cells? Now our next presentation was looking at our pipeline development, capitalizing on the observations we’ve. With the Bria-IMT therapy we’ve decided to take our cell line and some other cancer cell lines and to modify them so that they express different HLA types. I mentioned in our monotherapy and in our combination therapy experience with Bria-IMT, that there appears to be a clinical benefit associated with having an HLA match. With the Bria-IMT cell line. So by adding or…

iFrame is not supported! Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help patients with multiple myeloma? The data that I’m gonna present at the ASH meeting this year is relates to a specific cohort of the KarMMa trial called KarMMa-2 Cohort 2c. And this is a cohort that involves patients who had achieved suboptimal response following autologous stem cell transplantations. These are myeloma patients that have gone through initial induction therapy and stem cell transplantation, but have not achieved a complete remission. And these people were treated with…

Idecabtagene: ASH 2022 Multiple Myeloma Madhav Dhodapkar KarMMa-2 By Madhav Dhodapkar, MBBS What is Idecabtagene, and how can it help patients with multiple myeloma? The data that I’m gonna present at the ASH meeting this year is relates to a specific cohort of the KarMMa trial called KarMMa-2 Cohort 2c. And this is a cohort that involves patients who had achieved suboptimal response following autologous stem cell transplantations. These are myeloma patients that have gone through initial induction therapy and stem cell transplantation, but have not achieved a complete remission. And these people were treated with a single dose. Of…

iFrame is not supported! Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma Patients? ICARIA-MM study was a randomized phase 3 international trial in which we compared Pomalidomide/Dexamethasone to the combination of Isatuximab, Pomalidomide, Dexamethasone and we showed the significant PFS (progression-free survival) benefit. And very importantly at this meeting we presented a survival update, which showed significant survival gains. Now, one of the most important things about the drug is that Isatuximab is obviously similar to Daratumumab and when you have patients in whom Daratumumab was used after…

Isatuximab: ASH 2022 Multiple Myeloma Paul Richardson ICARIA By Paul Richardson, MD What can Pomalidomide/Dexamethasone do for Relapsed/Refractory Multiple Myeloma Patients? ICARIA-MM study was a randomized phase 3 international trial in which we compared Pomalidomide/Dexamethasone to the combination of Isatuximab, Pomalidomide, Dexamethasone and we showed the significant PFS (progression-free survival) benefit. And very importantly at this meeting we presented a survival update, which showed significant survival gains. Now, one of the most important things about the drug is that Isatuximab is obviously similar to Daratumumab and when you have patients in whom Daratumumab was used after they had progressed on…

iFrame is not supported! Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will this data analysis or data collection help with patients that receive omentum based reconstruction? One of the benefits that we’re noticing about this procedure is that patients really do not suffer any of the classical morbidities associated with donor sites. Prolonged drainage, large scars, and other deformities seem to have shortened the length of stay in the hospital, and again, there have been no donor sites or symptoms of donor site morbidities for many years. Dr. Nguyen and I recognized…

iFrame is not supported! Tumor-Associated Macrophages: BDC-3042 Animal Model Dr. Kenkel SITC 2022 What are tumor-associated macrophages? Our antibody that we refer to as BDC-3042 targets a molecule known as Dectin-2. This is a potent immune-activating receptor expressed by tumor-associated macrophages, or TAMs, across various types of human solid tumors. Dectin-2 is best known for its role in pathogen recognition and for stimulating immune responses against foreign pathogens. But here we’re actually trying to leverage this expression by TAMs to stimulate an immune response against the cancer rather than against some foreign pathogen. And we are targeting these TAMs using…

Tumor-Associated Macrophages: BDC-3042 Animal Model Dr. Kenkel SITC 2022 What are tumor-associated macrophages? Our antibody that we refer to as BDC-3042 targets a molecule known as Dectin-2. This is a potent immune-activating receptor expressed by tumor-associated macrophages, or TAMs, across various types of human solid tumors. Dectin-2 is best known for its role in pathogen recognition and for stimulating immune responses against foreign pathogens. But here we’re actually trying to leverage this expression by TAMs to stimulate an immune response against the cancer rather than against some foreign pathogen. And we are targeting these TAMs using our antibody, which specifically…

Omentum Based Reconstruction: For Pts with BMI < 25 kg/m Dr. Wapnir SABCS 2022 Will this data analysis or data collection help with patients that receive omentum based reconstruction? One of the benefits that we’re noticing about this procedure is that patients really do not suffer any of the classical morbidities associated with donor sites. Prolonged drainage, large scars, and other deformities seem to have shortened the length of stay in the hospital, and again, there have been no donor sites or symptoms of donor site morbidities for many years. Dr. Nguyen and I recognized that there was an…

iFrame is not supported! How will the decreases in circulating tumor associated cells help patients with metastatic breast cancer? The Other clinical trial looked at circulating tumor associated cells to look at progression-free survival, overall survival. In our pooled analysis of all of our Bria-IMT trials to date where we had done these analyses, we’ve been collaborating with Creative Microtech, Dan Adams is the first author on this poster, and they have developed a very interesting biomark called Cancer Associated Macrophage Like Cells, abbreviated CAMLs, and I’m sure many of you are familiar with circulating tumor cells as a biomarker…

SV-BR-1-GM: Pooled Analysis Predicts PFS and OS Dr. Williams SABCS 2022 How will the decreases in circulating tumor associated cells help patients with metastatic breast cancer? The Other clinical trial looked at circulating tumor associated cells to look at progression-free survival, overall survival. In our pooled analysis of all of our Bria-IMT trials to date where we had done these analyses, we’ve been collaborating with Creative Microtech, Dan Adams is the first author on this poster, and they have developed a very interesting biomark called Cancer Associated Macrophage Like Cells, abbreviated CAMLs, and I’m sure many of you are…

iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen receptor T-cell. So it’s a type of an immunogen therapy that targets BCMA, which is antigen on multiple myeloma. It is a first.Study until this hasn’t been used in other patients for other reasons or other indications. There are other BCMA car T-cell therapy but this is built differently to hopefully be more effective. And it is a phase 1 dose escalation first in human study.So this was we looked at patients who were defined as relapse refractory. So it…

iFrame is not supported! Axi-cel: Zuma 7 was a randomized phase three study By Armin Ghobadi, MD Zuma 7 was a randomized phase three study that used Axi-Cel versus a standard of. Care chemotherapy followed by autologous transplant.In a second line setting for most patients with relapsed refractory large B-cell lymphoma. That means adult patient with relapse refractory large B-cell lymphoma being refractory to the first line therapy or relapse within the first 12 months of therapy, they’re randomized to access lc, the 19 car versus the standard of care that was chemo followed by. Axi-Cel outcome was superior to…

iFrame is not supported! Car- T DDBMCA By Matthew Frigault, MD Car T cell DDBMCA is a autologous chimeric enogen receptor T-cell. So it’s a type of an immunogen therapy that targets BCMA, which is antigen on multiple myeloma. It is a first.Study until this hasn’t been used in other patients for other reasons or other indications. There are other BCMA car T-cell therapy but this is built differently to hopefully be more effective. And it is a phase 1 dose escalation first in human study.So this was we looked at patients who were defined as relapse refractory. So it…

Axi-cel: Zuma 7 was a randomized phase 3 study By Armin Ghobadi, MD Zuma 7 was a randomized phase three study that used Axi-Cel versus a standard of. Care chemotherapy followed by autologous transplant.In a second line setting for most patients with relapsed refractory large B-cell lymphoma. That means adult patient with relapse refractory large B-cell lymphoma being refractory to the first line therapy or relapse within the first 12 months of therapy, they’re randomized to access lc, the 19 car versus the standard of care that was chemo followed by. Axi-Cel outcome was superior to a standard of care,…

iFrame is not supported! Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called Advanced iv, which looked at Efgartigimod compared to placebo in a randomized controlled trial in patients with chronic ITP 18 years of age or. Efgartigimod or placebo intravenously over a 24 week trial All patients had failed at least one prior line of I t P therapy and were either on concurrent therapy that was not effective or had failed more than two lines of therapy. They were randomized two to one to receive Efgartigimod or placebo intravenously over a…

Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called Advanced iv, which looked at Efgartigimod compared to placebo in a randomized controlled trial in patients with chronic ITP 18 years of age or. Efgartigimod or placebo intravenously over a 24 week trial All patients had failed at least one prior line of I t P therapy and were either on concurrent therapy that was not effective or had failed more than two lines of therapy. They were randomized two to one to receive Efgartigimod or placebo intravenously over a 24 week trial. And…

LW-02 Cartridge: Immunicom Therapy Amir Jafri CEO and Founder What is the LW-02 Cartridge Therapy? Immunicom was actually formed in 2013. It actually was the byproduct of my wife who’s a physician here in San Diego. And not only her experiences with her patients but also personal experiences that she had, people that she knew in the community, friends of hers. That really drove her to, looking for a solution and particularly for cancer patients. That wasn’t toxic, that wasn’t gonna destroy the patient’s lives. And there was actually a friend of hers, she was a single mother…

iFrame is not supported! SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic Vaccine and how can it help patients with metastatic breast cancer? I want to introduce you to BriaCell and to our therapeutic approach. I’m gonna start by sharing my screen and show you, the way our therapy works. We’ve developed a cellular approach to cancer immunotherapy, that’s also a targeted approach. The way that it works is that we’ve isolated a breast cancer cell line. Which we call Bria-IMT, and this breast cancer cell line has multiple functions. It’s been…

SV-BR-1-GM: Whole Cell Therapeutic Vaccine Dr. Williams SABCS 2022 What is SV-BR-1-GM Whole Cell Therapeutic Vaccine and how can it help patients with metastatic breast cancer? I want to introduce you to BriaCell and to our therapeutic approach. I’m gonna start by sharing my screen and show you, the way our therapy works. We’ve developed a cellular approach to cancer immunotherapy, that’s also a targeted approach. The way that it works is that we’ve isolated a breast cancer cell line. Which we call Bria-IMT, and this breast cancer cell line has multiple functions. It’s been stably transected with the…

Inherited Thrombophilia: Pregnancy & Heparin – Middeldorp, MD- ASH 2022 By Saskia Middeldorp, MD I’m able to present the results of the ALIFE2 trial for you today. For everyone tomorrow. This trial investigated low molecular weight heparin and standard pregnancy care.First, a standard pregnancy care alone for women with recurrent miscarriage and inherited forms of Thrombophilia. , we have previously shown that in unexplained recurrent miscarriage antithrombotic therapy with low molecular heparin or aspirin does not help. in women with Thrombophilia in that trial, however, we noticed a relative risk of 31.31, so 30% more chances of having a live…

Zanubrutinib: Superior PFS in CLL Jennifer Brown, MD – ASH 2022 By Jennifer Brown, MD I’ll be discussing the alpine study today. By way of background, we note that Bruton tyrosine kinase inhibition and CLL has been transformative. Of its therapy because B-cell receptor signaling is required for tumor expansion and proliferation in CLL and B-cell lymphomas, and that B-cell receptor signaling is dependent on btk.Ibrutinib is the first in class covalent BTK inhibitor. Which did transform CLL therapy, but has properties that limit its use, particularly treatment discontinuation from toxicities with discontinuing rates of 16 to 23% across many…

Blinatumomab: ECOG-ACRIN E1910 National Clinical Trials Network Clinical trial By Mark Litzow, MD ECOG-ACRIN E1910 National Clinical Trials Network Clinical trial. This is a phase three randomized trial. Blinatumomab for newly diagnosed bcr A negative. We also refer to the bcr. Gene Rearrangement is a Philadelphia chromosome. So these patients were negative for this finding, but they had acute lymphoblastic leukemia. Acute lymphoblastic leukemias is the acute leukemia counterpart of what Dr.Brown just told you about chronic lymphocytic leukemia. And these are the detectable cancer cells that we worry about. These are the blast cells that don’t function. And cause…

iFrame is not supported! Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in the PACIFICA Clinical Trial in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis? The study we’re talking about is the PACIFICA study, which is a phase 3 randomized study of Pacritinib. The JAK2/IRAK1/ACVR1, ACVR1 inhibitor. Compared to best available therapy in patients who have platelet counts, myelofibrosis, patients who have platelet counts less than 50,000. And this is a clinical trial post-marketing, so the drug is now approved in the US with…

Pacritinib: Phase 3 PACIFICA Trial Dr. Mascarenhas ASH 2022 By John Mascarenhas, MD What is the study of Pacritinib in the PACIFICA Clinical Trial in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis? The study we’re talking about is the PACIFICA study, which is a phase 3 randomized study of Pacritinib. The JAK2/IRAK1/ACVR1, ACVR1 inhibitor. Compared to best available therapy in patients who have platelet counts, myelofibrosis, patients who have platelet counts less than 50,000. And this is a clinical trial post-marketing, so the drug is now approved in the US with a label for patients…

iFrame is not supported! Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN clinical trial that treated patients chronic phase chronic myeloid leukemia?  The Dasatinib is a tyrosine kinase inhibitor where we refer to as a second generation tyrosine kinase inhibitors. It’s a very potent inhibitor of B or able but it is also inhibits other kinases. It inhibits, CT PGA receptor it also inhibits SARC and it is more potent than Imatinib treatment. For example, the first generation TKI, and it was actually initially developed as the as…

Dasatinib or Imatinib: Final 5-Year Results From DASCERN Dr. Cortes ASH 2022 By Jorge Cortes, MD What is the DASCERN clinical trial that treated patients chronic phase chronic myeloid leukemia?  The Dasatinib is a tyrosine kinase inhibitor where we refer to as a second generation tyrosine kinase inhibitors. It’s a very potent inhibitor of B or able but it is also inhibits other kinases. It inhibits, CT PGA receptor it also inhibits SARC and it is more potent than Imatinib treatment. For example, the first generation TKI, and it was actually initially developed as the as a treatment for patients…

iFrame is not supported! Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib arm and the Danazol arm of the trial? It’s a great question, and Momelotinib has been around for a while. It is a JAK inhibitor primarily and was tested in two large randomized phase 3 trials. The SIMPLIFY-1 and 2, and both of those studies did not reach their primary endpoints, largely due to poor trial design. And ultimately, when the compound changed hands, it was sold to a couple of different companies, and now it…

Momelotinib: Update On MOMENTUM Trial Dr. Gerds ASH 2022 By Aaron Gerds, MD What is the difference between the Momelotinib arm and the Danazol arm of the trial? It’s a great question, and Momelotinib has been around for a while. It is a JAK inhibitor primarily and was tested in two large randomized phase 3 trials. The SIMPLIFY-1 and 2, and both of those studies did not reach their primary endpoints, largely due to poor trial design. And ultimately, when the compound changed hands, it was sold to a couple of different companies, and now it is resurrected. And…

iFrame is not supported! Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS What is the ZUMA-1 Cohort 6 clinical trials in large b-cell lymphoma (R/R LBCL)? So my study is title Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel), Axicabtagene Ciloleucel (Axi-Cel) also called Axu-Cell. It is FDA approved for the treatment of light cell lymphoma, and there are patients that develop cytokine release syndrome and neurological toxicity. And the question was whether this treatment that has been so effective can also be given in a safer way. In…

iFrame is not supported! Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480) help patients with multiple myeloma? The important point is that Mezigdomide (CC-92480) is an oral therapy that is a, what we call a new class of drugs called cell mods. These are highly potent small molecules which work by targeting the degradation of Ikaros and Aiolos, which are key transcription factors for multiple myeloma pathobiology. They’re also very important in lymphoma as well, actually. But in myeloma, they’re a key target. These the engagement or…

Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS What is the ZUMA-1 Cohort 6 clinical trials in large b-cell lymphoma (R/R LBCL)? So my study is title Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel), Axicabtagene Ciloleucel (Axi-Cel) also called Axu-Cell. It is FDA approved for the treatment of light cell lymphoma, and there are patients that develop cytokine release syndrome and neurological toxicity. And the question was whether this treatment that has been so effective can also be given in a safer way. In other words, maybe if…

Mezigdomnide Preliminary Results Multiple Myeloma from the Dose-Expansion Phase of the CC-92480-MM-001 By Paul Richardson, MD How can Mezigdomide (CC-92480) help patients with multiple myeloma? The important point is that Mezigdomide (CC-92480) is an oral therapy that is a, what we call a new class of drugs called cell mods. These are highly potent small molecules which work by targeting the degradation of Ikaros and Aiolos, which are key transcription factors for multiple myeloma pathobiology. They’re also very important in lymphoma as well, actually. But in myeloma, they’re a key target. These the engagement or the degradation of these…

iFrame is not supported! Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and how did COVID-19 impact multiple myeloma Patients? So this is a very interesting study in that it utilizes the Connect Multiple Myeloma Registry (Connect® MM Registry). The registry was established in 2009, and it’s one of the oldest and largest myeloma registries. We recruited (multiple myeloma) patients in 2 cohorts, 1500 (multiple myeloma patients) for the first cohort, followed by another cohort of 1500 (multiple myeloma patients). And what was unique about our registry is over…

Daratumumab: COVID-19 Impact – Robert Rifkin – ASH 2022 By Robert Rifkin, MD What is the Connect® MM Registry and how did COVID-19 impact multiple myeloma Patients? So this is a very interesting study in that it utilizes the Connect Multiple Myeloma Registry (Connect® MM Registry). The registry was established in 2009, and it’s one of the oldest and largest myeloma registries. We recruited (multiple myeloma) patients in 2 cohorts, 1500 (multiple myeloma patients) for the first cohort, followed by another cohort of 1500 (multiple myeloma patients). And what was unique about our registry is over time we’re able to…

iFrame is not supported! Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is it a clinical significance? Going back to around 2014, folks in our lab fully characterized clonal hematopoiesis of indeterminate potential, or CHIP. And this is a precursor to cancers like leukemia or classic syndromes—blood cancers that are very hard to treat once they’re identified. And so this really opened up a new potential for early interception and early prevention in acute leukemias, which is something we haven’t had before. We have this in the solid malignancies,…

Clonal Hematopoiesis: Myeloid Malignancy Prediction – ASH 2022 By LaChelle Weeks, MD, PhD What is clonal hematopoiesis and why is it a clinical significance? Going back to around 2014, folks in our lab fully characterized clonal hematopoiesis of indeterminate potential, or CHIP. And this is a precursor to cancers like leukemia or classic syndromes—blood cancers that are very hard to treat once they’re identified. And so this really opened up a new potential for early interception and early prevention in acute leukemias, which is something we haven’t had before. We have this in the solid malignancies, of course, with early…

iFrame is not supported! Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term follow-up data? Tamoxifen is a selective estrogen receptor modulator (SERMs). Which has been used firstly in the metastatic setting in women with advanced breast cancer, and then moved to the adjuvant setting where it show a survival advantage in estrogen receptor positive disease. The dose that was selected is 20 milligrams every day. And it is associated; it is a well tolerated drug, but has some serious adverse events, namely endometrial cancer, venous thromboembolic events, and most importantly, in…

Tamoxifen: TAM-01 Long Term Follow-up with Andrea De Censi SABCS 2022 What is TAM-01 long term follow-up data? Tamoxifen is a selective estrogen receptor modulator (SERMs). Which has been used firstly in the metastatic setting in women with advanced breast cancer, and then moved to the adjuvant setting where it show a survival advantage in estrogen receptor positive disease. The dose that was selected is 20 milligrams every day. And it is associated; it is a well tolerated drug, but has some serious adverse events, namely endometrial cancer, venous thromboembolic events, and most importantly, in the provincial setting, menopausal…

iFrame is not supported! Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San Antonia Breast Cancer Symposium) Thank you very much. Carlos. So it’s a pleasure to present the prime results of CAPItello-291 phase III study on behalf of my co-authors. Akt activation is very frequent in hormone receptor positive HER2-negative advanced breast cancer through genetic alterations in the pathway, but also make a current cancers without genetic alterations. AKT signaling is also implicated in the clinical development of endocrine (therapy) resistance. So Capivasertib was developed as a potent and selective inhibitor of…

iFrame is not supported! Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic Breast Cancer Patients? The EMERALD trial is a phase 3 clinical trial in women with ER-positive, HER2-negative metastatic breast cancer, were randomized after receiving and progressing on a CDK4/6 inhibitor to receive either Elacestrant, which is an oral SERT, or standard of care endocrine therapy, which was either Fulvestrant or an aromatase inhibitor depending on what endocrine therapy they had received previously. There were two primary endpoints for the trial. The first one was progression-free…

Elacestrant PFS Increase ER+ HER2- Dr. Kaklamani, MD SABCS 2022 What is the EMERALD Trial In ER-positive, HER2-negative Metastatic Breast Cancer Patients? The EMERALD trial is a phase 3 clinical trial in women with ER-positive, HER2-negative metastatic breast cancer, were randomized after receiving and progressing on a CDK4/6 inhibitor to receive either Elacestrant, which is an oral SERT, or standard of care endocrine therapy, which was either Fulvestrant or an aromatase inhibitor depending on what endocrine therapy they had received previously. There were two primary endpoints for the trial. The first one was progression-free survival, and the second…

iFrame is not supported! MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate immune system in many diseases, and our interests that we’re talking about today relate to cancer and the immunology of the tumor microenvironment. And it turns out it’s important because, It’s breast cancer, and in fact, it’s HER2+ breast cancer. HER2+ breast cancer is now with the modern therapies, half of all cancers. It is an aggressive form of cancer and there’s a lot of great solutions for these women with breast cancer, but they still relapse. And why…

iFrame is not supported! Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the opportunity to be here and present the firsthand results of the tool trial. So these are my disclosures. Camizestrant is a oral selective ER, degrader, and antagonist that has been tested in a phase 1 study, across a range of doses and has shown a very good profile of inhibition of the ER, and we designed SERENA-2 to assess different doses of Camizestrant in comparison with the standard of care with Fulvestrant in patients progressing to…

iFrame is not supported! Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a professor and chair of the Department of Medicine at the University of Rochester. And her presentation is evaluation of the breast cancer index in premenopausal women with early stage HR+ breast cancer in the soft trial. Thank you, Virginia. Good afternoon, everybody, and thank you for staying for this. What is the Breast Cancer Index (BCI)? So I’m happy to present the (BCI test) results of the analysis of Breast Cancer Index in premenopausal women…

Capivasertib: CAPItello-291 Results with Slides Nicholas Turner SABCS 2022 Presentation from the SABCS 2022 (San Antonia Breast Cancer Symposium) Thank you very much. Carlos. So it’s a pleasure to present the prime results of CAPItello-291 phase III study on behalf of my co-authors. Akt activation is very frequent in hormone receptor positive HER2-negative advanced breast cancer through genetic alterations in the pathway, but also make a current cancers without genetic alterations. AKT signaling is also implicated in the clinical development of endocrine (therapy) resistance. So Capivasertib was developed as a potent and selective inhibitor of all 3 Akt isoforms.…

Francois-Clement Bidard, MD, PhD of Institut Curiediscusses Circulating tumor cells enumeration and Health Related Quality of Life of patients treated with first-line chemotherapy for HER2 negative metastatic breast cancer

MUC4 Nude Mouse Model Trail in HER2+ Breast Cancer INmune Bio is focused on the innate immune system in many diseases, and our interests that we’re talking about today relate to cancer and the immunology of the tumor microenvironment. And it turns out it’s important because, It’s breast cancer, and in fact, it’s HER2+ breast cancer. HER2+ breast cancer is now with the modern therapies, half of all cancers. It is an aggressive form of cancer and there’s a lot of great solutions for these women with breast cancer, but they still relapse. And why am I saying HER2+…

Camizestrant: Results of the Randomized Phase 2 SERENA-2 Trial (with slides) Thank you, Carlos. Thank you, everyone, for the opportunity to be here and present the firsthand results of the tool trial. So these are my disclosures. Camizestrant is a oral selective ER, degrader, and antagonist that has been tested in a phase 1 study, across a range of doses and has shown a very good profile of inhibition of the ER, and we designed SERENA-2 to assess different doses of Camizestrant in comparison with the standard of care with Fulvestrant in patients progressing to prior endocrine therapy. So…

Yen-Shen Lu, MD of National Taiwan University discusses Ribociclib and the Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

RxPONDER trial (SWOG S1007) at SABCS 2022 presented by Yara Abdou, MD from the University of North CarolinaGS1-01 Race and clinical outcomes in the RxPONDER trial (SWOG S1007)Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU,

Getting description

Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O’Reagan What is the Breast Cancer Index? Ruth Regan, who is a professor and chair of the Department of Medicine at the University of Rochester. And her presentation is evaluation of the breast cancer index in premenopausal women with early stage HR+ breast cancer in the soft trial. Thank you, Virginia. Good afternoon, everybody, and thank you for staying for this. What is the Breast Cancer Index (BCI)? So I’m happy to present the (BCI test) results of the analysis of Breast Cancer Index in premenopausal women who enrolled in the…

HER2-Low: Anastrozole TRIO-US B-12 TALENT SABCS 2022Aditya Bardia, MD of Mass General discusses theGS2-03: TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer

Trastuzumab emtansine versus Trastuzumab deruxtecan versus in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Sara A. Hurvitz, MD, UCLA Health discusses the released data for Phase 3 study entitled DESTINY-Breast03 at SABCS 2022

Trastuzumab deruxtecan DESTINY-Breast02 results presented at SABCS 2022 with Ian E. Krop, MD, PhD Yale School of Medicine.GS2-01: Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02 With Slides

SABCS 2022 Day 2 Press Conference December 7, 2022. Ian E. Krop, MD, PhD from Yale University discusses Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02Sara Hurvitz, MD from UCLA Health discusses Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03Aditya Bardia, MD, MPH from Massachusetts General Hospital discusses TRIO-US B-12 TALENT: Neoadjuvant trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer